The company, a unit of French drug maker Sanofi-Aventis, said total sales slid 9% on the year to RON183.5 million.
Zentiva posted total revenue of RON200.3 million in the January-September period, down 3% on the year, while overall costs rose 8% to RON148.5 million.
The company has a share capital of RON41.6 million split into 416.9 million shares with a face value of RON0.1.
French group Sanofi-Aventis owns 74.9% in Zentiva Romania.
On the Bucharest bourse Tuesday, Zentiva closed up 0.35% at RON0.871 a share. (EUR1=RON4.3487)